ALURD — Allurion Technologies Share News
0.000.00%
Last trade - 00:00- $7.48m
- $30.98m
- $15.23m
Brief: Allurion Intends To Appeal NYSE Notice Of Delisting, Execute Plan To Regain Compliance, And Expects To Continue Trading On NYSE
Brief: NYSE To Commence Delisting Proceedings Against Allurion Technologies, Inc.
Allurion rises on plan to offer discounted weight-loss drug Mounjaro in Argentina
Allurion rises after strong weight-loss data from combination therapy
Brief: Allurion Announces Strategic Distribution Partnership With Prosurg Medical In Brazil To Pioneer New Approach Focused On Metabolically Healthy Weight Loss
Allurion Technologies Q3 revenue beats expectations
Brief: Allurion Technologies Q3 Revenue USD 2.658 Million
Brief: Allurion Announces Landmark Peer-Reviewed Publication On Consecutive Use Of The Allurion Smart Capsule
Brief: Medtimo Filed Patent Infringement Complaint In U.S. District Court Of District Of Delaware Against Allurion Technologies
Allurion Technologies Inc expected to post a loss of 78 cents a share - Earnings Preview
Allurion Technologies Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: Allurion Technologies Inc On August 5, Co Announced Strategic Restructuring Plan Which Includes Reduction In Workforce By 65% - SEC Filing
Brief: Allurion Shifts Strategy Toward Low-Dose GLP-1 Combos, Muscle Health and US Entry
Allurion Technologies jumps on Canadian weight-loss partnership
Allurion Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Allurion Technologies Inc expected to post a loss of $8.58 a share - Earnings Preview
Allurion Technologies Inc reports results for the quarter ended December 31 - Earnings Summary
Allurion Technologies Inc expected to post a loss of $5.17 a share - Earnings Preview
Allurion Technologies jumps on initial data from weight-loss device treatment